Objectives: This study sought to assess the utility of the Destination Therapy Risk Score (DTRS) in patients with continuous flow left ventricular assist devices (LVAD). Background: The DTRS was developed to predict the risk of 90-day in-hospital mortality with pulsatile flow LVAD as destination therapy (DT). Despite ongoing use in patients with continuous flow devices, its utility has not been studied in such populations. Methods: The DTRS was determined in 1,124 patients with the continuous flow HeartMate II (Thoratec Corporation, Pleasanton, California) LVAD as a bridge to transplant (BTT, n = 486) and DT (n = 638) and 114 DT patients with the pulsatile flow HeartMate XVE (Thoratec Corporation). Patients were divided into risk groups based on DTRS: low (0-8), medium (9-16), and high (>16). Results: The 90-day in-hospital mortality for low-, medium-, and high-risk groups was 8%, 7%, and 16%, respectively, for BTT patients; 9%, 12%, and 19%, respectively, for DT patients; and 11%, 18%, and 25%, respectively, for XVE DT patients. The high-risk groups had more than a 2-fold increased risk of mortality compared with the low-risk groups. However, the area under the receiver-operating characteristic curve for 90-day in-hospital mortality yielded modest values ranging from 0.54 to 0.58 for the HeartMate II BTT and DT groups, respectively. Survival rates over 2 years were statistically significantly different as stratified by the 3 DTRS groups for patients implanted for DT but not for BTT. Conclusions: DTRS provides poor discrimination of mortality for BTT patients and only modest discrimination for DT patients receiving continuous flow LVAD.
Bibliographical noteFunding Information:
Drs. Ewald, Miller, Tatooles, and Rogers are consultants for Thoratec Corporation. Dr. Adamson is a speaker for Thoratec Corporation. Dr. Miller also receives research support from Thoratec Corporation. Dr. Tatooles also received research grants from Thoratec Corporation and Heartware . Drs. Sundareswaran and Farrar are employees of Thoratec Corporation. Dr. Farrar is also a stockholder in Thoratec Corporation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- left ventricular assist device
- mechanical circulatory support
- risk stratification